OTCMKTS:MDIT Medite Cancer Diagnostics (MDIT) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free MDIT Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsStock AnalysisChartFinancialsSEC Filings Get Medite Cancer Diagnostics alerts: Email Address Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Medite Cancer Diagnostics Stock (OTCMKTS:MDIT)Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.Read More Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report MDIT Stock News HeadlinesSeptember 26, 2023 | finance.yahoo.comCleveland Diagnostics Announces Prostate Cancer Awareness Month Campaign: ‘A PSA on PSA’September 2, 2023 | finance.yahoo.comPancreatic Cancer Diagnostics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028April 25, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”August 23, 2023 | finance.yahoo.comBreast Cancer Diagnostics Market to Grow Rapidly at a CAGR of 8.7% by 2030 | DataM IntelligenceAugust 18, 2023 | yahoo.comHere's why some people keep their cancer diagnosis to themselves: 'An incredibly personal decision'May 10, 2023 | msn.comA New Urine Test Could Be a Simple Way to Check For CancerApril 11, 2023 | msn.comPromising new AI can detect early signs of lung cancer that doctors can't seeMarch 17, 2023 | benzinga.comLiver Cancer Diagnostics Market Value to Experience over 2x Growth; Liver Function Tests (LFTs) Key Approach to Detect Malignancy: Fact.MRApril 25, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”March 11, 2023 | finance.yahoo.comCancer Diagnostics Global Market Report 2023February 23, 2023 | yahoo.comCancer Diagnostics Market Size Will Reach USD 332.4 Billion by 2032 - Market.usFebruary 21, 2023 | marketwatch.comForecasting the Future of Noninvasive Cancer Diagnostics Market 2023: Regional Trends and Industry DevelopmentsFebruary 19, 2023 | marketwatch.comNoninvasive Cancer Diagnostics Technology Market: Exploration of the Top Regions and Players with OpportunitiesFebruary 18, 2023 | finance.yahoo.comCervical Cancer Diagnostics Global Market Report 2023February 18, 2023 | marketwatch.comProstate Cancer Diagnostics Market 2023: Emerging Trends and Best Practices in Futurism till 2028January 19, 2023 | finance.yahoo.comGlobal Prostate Cancer Diagnostics Market to Reach $8.8 Billion by 2027January 16, 2023 | forbes.comMIT & Mass General Hospital Have Developed An AI System That Can Detect Lung CancerJanuary 11, 2023 | benzinga.comBreast Cancer Diagnostics Global Market Report 2023: Industry to Reach $6.16 Billion by 2027 at a 6.67% CAGRJanuary 11, 2023 | finance.yahoo.comCancer Diagnostic Market will reach to USD 276.62 billion by 2029 : GreyViewsOctober 4, 2022 | mirror.co.ukSisters receive shock cancer diagnosis within just six weeks of each otherSeptember 20, 2022 | reuters.comMedite Cancer Diagnostics IncJuly 29, 2021 | barrons.comMedite Cancer Diagnostics Inc.See More Headlines Receive MDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medite Cancer Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolOTCMKTS:MDIT CUSIPN/A CIK75439 Webwww.medite-group.com Phone(407) 996-9630Fax407-996-9631Employees69Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Jeffrey Rencher (Age 57)Chief Marketing & Business Development Officer Comp: $95.6kKey CompetitorsLombard MedicalOTCMKTS:EVARFSafeplus InternationalOTCMKTS:ACAIMymeticsOTCMKTS:MYMXRegeneRx BiopharmaceuticalsOTCMKTS:RGRXSienna BiopharmaceuticalsOTCMKTS:SNNAQView All Competitors MDIT Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Medite Cancer Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medite Cancer Diagnostics investors own include Cracker Barrel Old Country Store (CBRL), Banyan Gold (BYN), Blackstone Mortgage Trust (BXMT), Invesco BulletShares 2020 Corporate Bond ETF (BSCK), Bank of Marin Bancorp (BMRC), BlackRock (BLK), Avon Products (AVP), Grupo Aeroportuario del Sureste, S. A. B. de C. V. (ASR), Armada Hoffler Properties (AHH) and Atlantic Gold (AGB). How do I buy shares of Medite Cancer Diagnostics? Shares of MDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MDIT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medite Cancer Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
